Elotuzumab in the treatment of relapsed and refractory multiple myeloma. Future Oncol., 2021
Outcome of a real-life population of patients with acute promyelocytic leukemia treated according to the PETHEMA guidelines: the Polish Adult Leukemia Group (PALG) experience.Clin.Lymphoma Myeloma Leuk, 2020
Heat shock proteins as a new, promising target of multiple myeloma therapyExpert, Review of Hematology, 2020
Ofatumumab maintenance prolongs progression-free survival in relapsed chronic lymphocytic leukemia: final analysis of the PROLONG study, Blood Cancer Journal, 2019
Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study, British journal of haematology, 2019
Epidemiologia przewlekłej niewydolności żylnej na podstawie zgłaszalności absencji chorobowej w zakładzie ubezpieczeń społecznych.Publ.Health Forum, 2019
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).Leukemia & lymphoma, 2019
Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study.Leukemia, 2019
All-oral ixazomib, cyclophosphamide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma.European journal of cancer (Oxford, England : 1990),2018
Phase 2 study of all-oral ixazomib, cyclophosphamide and low-dose dexamethasone for relapsed/refractory multiple myeloma.British journal of haematology, 2018
Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.The New England journal of medicine, 20118
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.Leukemia,2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studies.American journal of hematology, 2018
Recommendations for the diagnosis and treatment of patients with polycythaemia vera.European journal of haematology, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.Haematologica, 2018
The importance of antiangiogenic effect in multiple myeloma treatment.Advances in clinical and experimental medicine : official organ Wroclaw Medical University, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS study.Leukemia & lymphoma, 2018
Evaluation on inflammatory states of peripheral veins connected with cannulation /Przeglad epidemiologiczny, 2018
Improving the effectiveness of obesity treatment by combining a diet and motivational techniquesRoczniki Panstwowego Zakladu Higieny, 2018
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma.The New England journal of medicine, 2017
Eltrombopag for advanced myelodysplastic syndromes or acute myeloid leukaemia and severe thrombocytopenia (ASPIRE): a randomised, placebo-controlled, phase 2 trial.The Lancet. Haematology,2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control study.Annals of hematology, 2017
Elotuzumab plus lenalidomide/dexamethasone for relapsed or refractory multiple myeloma: ELOQUENT-2 follow-up and post-hoc analyses on progression-free survival and tumour growth.British journal of haematology, 2017
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.American journal of hematology, 2017
Biomarkers in Immunoglobulin Light Chain Amyloidosis.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2017
Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti, 2017
Health-related quality of life and patient-reported outcomes of ofatumumab plus fludarabine and cyclophosphamide versus fludarabine and cyclophosphamide in the COMPLEMENT 2 trial of patients with relapsed CLL.Leukemia & lymphoma, 2016
Ofatumumab plus fludarabine and cyclophosphamide in relapsed chronic lymphocytic leukemia: results from the COMPLEMENT 2 trial.Leukemia & lymphoma, 2016
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.British journal of haematology, 2016
Concomitance of monosomal karyotype with at least 5 chromosomal abnormalities is associated with dismal treatment outcome of AML patients with complex karyotype - retrospective analysis of Polish Adult Leukemia Group (PALG).Leukemia & lymphoma, 2016
Health-related quality of life and patient-reported outcomes of ofatumumab plus chlorambucil versus chlorambucil monotherapy in the COMPLEMENT 1 trial of patients with previously untreated CLL.Acta oncologica (Stockholm, Sweden), 2016
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.The New England journal of medicine, 2016
A phase 2, multicenter study investigating ofatumumab and bendamustine combination in patients with untreated or relapsed CLL.American journal of hematology, 2016
Elotuzumab: a novel immune-stimulating therapy to treat multiple myeloma.Expert review of hematology, 2016
Phase III, randomized study of ofatumumab versus physicians' choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia.Leukemia & lymphoma, 2016
Analysis of occupational exposures to blood registered in the General Hospital in Zabrze in the years 2006-2015Przeglad epidemiologiczny, 2016
Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre studyThe Lancet Oncology, 2016
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.The New England journal of medicine, 2015
Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.The Lancet. Oncology, 2015
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.Blood, 2015
Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: a retrospective, multicenter Polish Adult Leukemia Group study.American journal of hematology, 2015
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study.The Lancet. Oncology, 2015
FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.Annals of oncology : official journal of the European Society for Medical Oncology, 2015
CEBPA copy number variations in normal karyotype acute myeloid leukemia: Possible role of breakpoint-associated microhomology and chromatin status in CEBPA mutagenesis.Blood cells, molecules & diseases, 2015
Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.The New England journal of medicine, 2015
A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.Leukemia & lymphoma, 2015
Ofatumumab for the treatment of chronic lymphocytic leukemia.Expert review of hematology, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial.Lancet (London, England), 2015
Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study.Haematologica, 2015
2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma.Blood, 2014
Bortezomib for the treatment of multiple myeloma.Expert review of hematology, 2014
Association of circulating regulatory T cell number with the incidence and prognosis of diffuse large B-cell lymphoma.European journal of haematology, 2013
Intermediate-dose Ara-C plus G-CSF for stem cell mobilization in patients with lymphoid malignancies, including predicted poor mobilizers.Bone marrow transplantation, 2013
Management of multiple myeloma-related bone disease.Przeglad lekarski, 2013
Necessary diagnostic requirements and therapeutic recommendations in multiple myeloma].Przeglad lekarski, 2013
Different prognosis of acute myeloid leukemia harboring monosomal karyotype with total or partial monosomies determined by FISH: retrospective PALG study.Leukemia research, 2012
Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma.Haematologica, 2012
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2012
Subcutaneous bortezomib as a new promising way to successful maintenance therapy in multiple myeloma.Wiadomosci lekarskie (Warsaw, Poland : 1960), 2012
Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study.The Lancet. Oncology, 2011
The early reduction of leukemic blasts in bone marrow on day 6 of induction treatment is predictive for complete remission rate and survival in adult acute myeloid leukemia; the results of multicenter, prospective Polish Adult Leukemia Group study.American journal of hematology, 2011
Spontaneous remission of Kikuchi-Fujimoto disease (lymphadenopathy) with focal skin parakeratosis.Wiadomosci lekarskie (Warsaw, Poland : 1960), 2009
Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.Annals of hematology, 2007
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.European journal of haematology, 2007
Clinical importance of angiogenesis and angiogenic factors in oncohematology.Wiadomosci lekarskie (Warsaw, Poland : 1960), 2007
The results of imatinib therapy for patients with primary eosinophilic disorders.European journal of haematology, 2006
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.Transplantation proceedings, 2005
A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.Annals of hematology, 2005
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.Leukemia, 2004
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).European journal of haematology, 2003
G-CSF administered in time-sequenced setting during remission induction and consolidation therapy of adult acute lymphoblastic leukemia has beneficial influence on early recovery and possibly improves long-term outcome: a randomized multicenter study.Leukemia & lymphoma, 2002
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study.Medical oncology (Northwood, London, England), 2001
dr n. med. Martyna Bednarczyk
Elotuzumab in the treatment of relapsed and refractory multiple myeloma. Future Oncol., 2021
The expression patterns of BECN1, LAMP2, and PINK1 genes in colorectal cancer are potentially regulated by micrornas and CpG islands: An in silico study, J.Clin.Med., 2020
Heat shock proteins as a new, promising target of multiple myeloma therapyExpert, Review of Hematology, 2020
Expression profile of genes associated with the proteins degradation pathways in colorectal adenocarcinoma.Curr.Pharm.Biotechnol., 2019
Genes involved in the regulation of different types of autophagy and their participation in cancer pathogenesis, Oncotarget, 2018
Autophagy-related gene expression in colorectal cancer patients, J.Biol.Regul.Homeost.Agents, 2017
Profile of gene expression of TLR-signaling pathways in colorectal cancer tissues, Int.J.Immunopathol.Pharmacol., 2017
The characterization of tumor necrosis factor alpha (TNF-α), its role in cancerogenesis and cardiovascular system diseases and possibilities of using this cytokine as a molecular marker, Acta Univ.Lodz. Folia Biol.Oecol., 2017
The transcriptional activity of LAMP3 gene involved in autophagocytosis in colorectal cancer LAMP3 expression in colorectal cancer, J.Biosc.Med., 2017
Expression of migration-related genes in human colorectal cancer and activity of a disintegrin and metalloproteinase 17, Biomed Res.Int., 2016
TOLL - like receptors signaling pathways using MyD88, Folia Med.Cassov., 2015